Evidence map›Paper›PMID 21253011›Full record

ArticlePLoS medicine2010

Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study.

David R Boulware, David B Meya, Tracy L Bergemann, Darin L Wiesner, Joshua Rhein, Abdu Musubire, Sarah J Lee, Andrew Kambugu, Edward N Janoff, Paul R Bohjanen

Open access · goldAbstract read
In one paragraph

Article in PLoS medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 1 synthesis or guideline pooled it, 280 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Revisiting Immune-Mediated Mechanisms as Drivers of Cryptococcal Immune Reconstitution Inflammatory Syndrome.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

David R BoulwareDivision of Infectious Diseases & International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. boulw001@umn.edu
David B Meya
Tracy L Bergemann
Darin L Wiesner
Joshua Rhein
Abdu Musubire
Sarah J Lee
Andrew Kambugu
Edward N Janoff
Paul R Bohjanen
University of Minnesota · USMakerere University · UGUniversity of Colorado Denver · US

Funding

Scholar Development Clinical Research (RMI)K12RR023247 · NCRR · UNIVERSITY OF MINNESOTA TWIN CITIES · PI LUEPKER, RUSSELL V · 2005 to 2009
$13.5M
Infectious Disease Training in Clinical InvestigationT32AI055433 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI David R Boulware · 2003 to 2026
$6.1M
Immune Reconstitution Syndrome in HIV infected Persons in Resource-Limited AreasK23AI073192 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R · 2009 to 2012
$530k
Trial for the Optimal Timing of HIV Therapy after Cryptococcal MeningitisR34AI081554 · NIAID · UNIVERSITY OF MINNESOTA · PI BOHJANEN, PAUL R, BOULWARE, DAVID R · 2009 to 2009
$180k
HIV Immune Reconstitution Inflammatory Syndrome in UgandaR03AI078750 · NIAID · UNIVERSITY OF MINNESOTA · PI BOHJANEN, PAUL R · 2008 to 2009
$151k
NCRR NIH HHS K12 RR023247NCRR NIH HHS K12RR023247-04NIAID NIH HHS K23 AI073192NIAID NIH HHS K23AI073192NIAID NIH HHS L30 AI066779NIAID NIH HHS L30AI066779NIAID NIH HHS R03 AI078750NIAID NIH HHS R03AI078750NIAID NIH HHS R34 AI081554NIAID NIH HHS T32 AI055433NIAID NIH HHS T32AI055433-03
6 · The paper itself

Abstract

backgroundAlthough antiretroviral therapy (ART) improves survival in persons with cryptococcal meningitis (CM) and AIDS, ART frequently elicits HIV immune reconstitution inflammatory syndrome (IRIS), an exaggerated and frequently deadly inflammatory reaction that complicates recovery from immunodeficiency. The pathogenesis of IRIS is poorly understood and prediction of IRIS is not possible. METHODS AND

findingsWe prospectively followed 101 ART-naïve Ugandans with AIDS and recent CM for one year after initiating ART, and used Luminex multiplex assays to compare serum cytokine levels in participants who did or did not develop IRIS. IRIS occurred in 45% of participants with recent CM on ART, including 30% with central nervous system (CNS) manifestations. The median time to CM-IRIS was 8.8 wk on ART. Overall mortality on ART was 36% with IRIS and 21% without IRIS. CM-IRIS was independently associated with death (HR = 2.3, 95% CI 1.1-5.1, p = 0.04). Patients experiencing subsequent CM-IRIS had 4-fold higher median serum cryptococcal antigen (CRAG) levels pre-ART (p = 0.006). Higher pre-ART levels of interleukin (IL)-4 and IL-17 as well as lower tumor necrosis factor (TNF)-α, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and vascular endothelial growth factor (VEGF) predicted future IRIS in multivariate analyses (area under the curve [AUC] = 0.82). An algorithm based on seven pre-ART serum biomarkers was a robust tool for stratifying high (83%), moderate (48%), and low risk (23%) for IRIS in the cohort. After ART was initiated, increasing levels of C-reactive protein (CRP), D-dimer, IL-6, IL-7, IL-13, G-CSF, or IL-1RA were associated with increasing hazard of IRIS by time-to-event analysis (each p≤0.001). At the time of IRIS onset, multiple proinflammatory cytokine responses were present, including CRP and IL-6. Mortality was predicted by pre-ART increasing IL-17, decreasing GM-CSF, and CRP level >32 mg/l (highest quartile). Pre-ART CRP level >32 mg/l alone was associated with future death (OR = 8.3, 95% CI 2.7-25.6, p<0.001).

conclusionsPre-ART increases in Th(17) and Th(2) responses (e.g., IL-17, IL-4) and lack of proinflammatory cytokine responses (e.g., TNF-α, G-CSF, GM-CSF, VEGF) predispose individuals to subsequent IRIS, perhaps as biomarkers of immune dysfunction and poor initial clearance of CRAG. Although requiring validation, these biomarkers might be an objective tool to stratify the risk of CM-IRIS and death, and could be used clinically to guide when to start ART or use prophylactic interventions.

Indexed as

Cohort StudiesGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHIV InfectionsHumansImmune Reconstitution Inflammatory SyndromeInterleukin-17Interleukin-4Meningitis, CryptococcalProspective StudiesTumor Necrosis Factor-alphaGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-17Interleukin-4Tumor Necrosis Factor-alpha

Identifiers

PMID21253011
PMCPMC3014618
OpenAlexW2156120863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.